TransCode Therapeutics, Inc. has announced it has secured $25,000,000 in investment capital from investors. This funding round marks a significant step for the company as it continues its efforts to develop and advance innovative cancer therapies. The capital infusion is intended to accelerate the development of its therapeutic candidates and expand its proprietary drug delivery platform.
TransCode Therapeutics is focused on delivering a cancer-free future by designing and efficiently delivering targeted therapeutics. The company's core belief is that cancer can be overcome through intelligent design. Its lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), which is considered a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, and glioblastomas.
The company's proprietary TTX delivery platform is designed to transport targeted therapeutics directly to cancer cells, addressing a critical barrier in cancer treatment. TransCode believes this technology opens the door to a broad array of cancer therapies. This new funding will support the ongoing development of its pipeline of drug candidates and further optimization of its TTX platform.
TransCode Therapeutics plans to use the funds for growth initiatives, including advancing its rapidly expanding platform of drug candidates. With this investment, the company reinforces its commitment to its mission, aiming to target a variety of tumor indications with the goal of achieving long-term treatment survival for cancer patients.
